Drug Type Monoclonal antibody |
Synonyms Deuterated enzalutamide analog/PD-1 checkpoint inhibitor |
Target |
Action antagonists, inhibitors |
Mechanism AR antagonists(Androgen Receptor antagonists), PD-1 inhibitors(Programmed cell death protein 1 inhibitors) |
Therapeutic Areas |
Active Indication- |
Inactive Indication |
Originator Organization |
Active Organization- |
Inactive Organization |
License Organization- |
Drug Highest PhasePendingPreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Breast Cancer | Preclinical | China | 12 Feb 2019 | |
Metastatic castration-resistant prostate cancer | Preclinical | China | 12 Feb 2019 |